Thelansis

Giant Cell Arteritis (GCA) Market Outlook Thelansis’s “Giant Cell Arteritis (GCA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Giant Cell Arteritis (GCA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market...

Giant Cell Arteritis (GCA) Market Outlook Thelansis’s “Giant Cell Arteritis (GCA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Giant Cell Arteritis (GCA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Giant Cell Arteritis (GCA) Overview Giant cell arteritis (GCA), or cranial or temporal arteritis, is a type of immune-mediated inflammation affecting medium to large arteries. It is commonly seen in older adults over 50, with an average age of 70, and primarily affects the cranial arteries, aorta and its branches. The underlying immunopathology involves the activation of T cells and the release of cytokines, including interleu...

 Giant cell arteritis (GCA), or cranial or temporal arteritis, is a type of immune-mediated inflammation affecting medium to large arteries. It is commonly seen in older adults over 50, with an average age of 70, and primarily affects the cranial arteries, aorta and its branches. The underlying immunopathology involves the activation of T cells and the release of cytokines, including interleukins and gamma interferon. The presence of HLA DR4-01 suggests a role for antigen selection and presentation in its pathogenesis. Clinical manifestations of GCA may include fever, headaches, vision loss, limb claudication, anorexia, fatigue and weight loss. The disease can last months to years and may result in vision loss and thoracic aneurysms. Glucocorticosteroids are the standard treatment, with rapid response seen with a typical initial dose of 60mg prednisone per day. ·        Giant cell arteritis is the most common vasculitis in adulthood, with an annual i...

 Giant cell arteritis (GCA), or cranial or temporal arteritis, is a type of immune-mediated inflammation affecting medium to large arteries. It is commonly seen in older adults over 50, with an average age of 70, and primarily affects the cranial arteries, aorta and its branches. The underlying immunopathology involves the activation of T cells and the release of cytokines, including interleukins and gamma interferon. The presence of HLA DR4-01 suggests a role for antigen selection and presentation in its pathogenesis. Clinical manifestations of GCA may include fever, headaches, vision loss, limb claudication, anorexia, fatigue and weight loss. The disease can last months to years and may result in vision loss and thoracic aneurysms. Glucocorticosteroids are the standard treatment, with rapid response seen with a typical initial dose of 60mg prednisone per day. ·        Giant cell arteritis is the most common vasculitis in adulthood, with an annual i...